Mylan Inc. (MYL) said its subsidiary Mylan Laboratories Limited received tentative approval from FDA for its New Drug Application for Abacavir Sulfate and Lamivudine Tablets, 60 mg/30 mg. This fixed-dose combination is intended to treating children with HIV/AIDS. The approval is under the President's Emergency Plan for AIDS Relief or PEPFAR.
The combination is based on the adult-strength, brand version of the product Epzicom, by Viiv Healthcare.
Mylan also has received approval for this pediatric FDC therapy from the World Health Organization under their Prequalification of Medicines Programme.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.